Wedbush upgraded PulteGroup Inc (NYSE:PHM) to "outperform" from "neutral" given an overdone stock price decline and strong ...

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this ...

Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm notes Blueprint Medicines reported HV data for BLU ...

Wedbush reaffirmed their neutral rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has ...

WingStop has been added to the Wedbush Best Ideas List, with the firm forecasting strong growth potential for the company in ...

Arhaus, Inc. (NASDAQ:ARHS – Free Report) – Investment analysts at Wedbush lifted their FY2024 earnings per share estimates for Arhaus in a research note issued to investors on Friday ...

The AI revolution continues to reshape the tech landscape, with Wedbush analysts recently predicting a 25% surge in tech ...

Concerns over the 10-year Treasury yield nearing 5% and a less dovish Federal Reserve outlook for 2025 have spurred risk-off ...

On Monday, Analysts at Wedbush said a recent tech pullback, triggered by surging Treasury yields and the Federal Reserve's less dovish-eyed view towards 2025, is being viewed as a strategic buying ...

The last item of consequence is the expense ratio. The Vanguard Information Technology ETF has an expense ratio of 0.1%, ...

As the Jan. 19 date for a TikTok ban approaches, another name is emerging as a potential buyer: SpaceX and Tesla CEO Elon ...